NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG
Wissenschaftlicher Artikel
Authors
Schnaiter, Andrea
Paschka, Peter
Rossi, Marianna
Zenz, Thorsten
Buehler, Andreas
Faculties
Medizinische FakultätInstitutions
UKU. Klinik für Innere Medizin IIIPublished in
Blood ; 122 (2013), 7. - S. 1266-1270. - ISSN 0006-4971
Link to publication
https://dx.doi.org/10.1182/blood-2013-03-488197Funding information
Else Kroner Fresenius Stiftung (Else Kroner Forschungskolleg Ulm)
CLL Global Research Foundation (Alliance)
Virtual Helmholtz Institute [VH-VI-404, TP2]
DFG [SFB 1074]
CLL Global Research Foundation (Alliance)
Virtual Helmholtz Institute [VH-VI-404, TP2]
DFG [SFB 1074]